The AIDS Healthcare Foundation...mounted a new advocacy campaign yesterday challenging Cipla for an alleged price disparity between what the firm charges for its generic drugs in India vs. Africa. Cipla refuted the over-pricing charges in ads of its own, adding that it is “consulting our legal experts.”... AHF said other Indian drug makers aren't immune from similar price reviews, naming Ranbaxy, Emcure, Aurobindo and Genex, but that it initially targeted Cipla because it's the largest.